GlioVector™ : A targeted delivery technology for the treatment of brain cancers
Targeted delivery for the treatment of tumors of the central nervous system
Efficient treatment of brain tumors remains a major medical challenge. One important hurdle is low drug selectivity and low drug uptake over biological barriers.
Targeted delivery strategies represent one approach to improve delivery of drugs to the CNS while reducing adverse side-effects related to drug accumulation in non-target cells and tissues.
GlioVector™ “Leads the Way”
GlioVector™ is a proprietary vectorization technology related to the family of Cell Penetrating Peptides (CPPs). It acts as a guidance system making it possible to target and selectively penetrate three major cell types: glioma cells and brain tumor initiating cells.
GlioVector™ is based on a 24 amino acid peptide corresponding to the binding site of tubulin on the light subunit of neurofilaments. It is a highly conserved sequence between species which presents itself in the form of a β sheet in the extra-cellular matrix.
GlioVector™ allows the vectorization of active ingredients or nanomedicines by giving them specificity for brain tumors of the glioma family.
GlioVector™ has already been conjugated to lipid nanocapsules loaded with anticancer drugs, neuroprotective drugs, or fluorescent markers, improving their selectivity and cellular uptake both in vitro and in vivo.
Examples of diseases for which GlioVector™ could be used for the development of new therapeutic strategies :
- Glioblastoma
- Neuroblastoma
- Medulloblastoma
- Pediatric high-grade gliomas (e.g. DMG/DIPG)
- Metastatic brain tumors
Please contact us to get more information regarding our GlioVector™ technology.
Academic Publications and Patents:
NFL-TBS.40–63 peptide targets and kills glioblastoma stem cells derived from human patients and also targets nanocapsules into these cells. Lépinoux-Chambaud, C. et al. International Journal of Pharmaceutics – 2019
The Neurofilament-Derived Peptide NFL-TBS.40-63 Targets Neural Stem Cells and Affects Their Properties. Lépinoux-Chambaud, C. et al. Stem Cells Translational Medicine – 2016
The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis. Lépinoux-Chambaud, C. et al. International Journal of Pharmaceutics – 2013
WO2011/073207 Use of a neurofilament Peptide for the treatment of Glioma